| abstract |
An antibody, or antigen-binding fragment thereof, that binds to human complement C5 for use in a method of treating paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic-uremic syndrome (aHUS) in a human, comprising the method: (i) administering to the human a siRNA specific for the mRNA encoding human C5 to thereby reduce the concentration of C5 in the human serum, followed by; (ii) administering the C5 antibody or fragment thereof to the human, wherein a reduced concentration of C5 in the human serum increases the serum half-life of the C5 antibody or fragment thereof administered to the human. |